



Company Announcement  
No. 9/2013

## Zealand Pharma announces change in management

Copenhagen, 15 March 2013 – Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, announces that Christian Grøndahl, Executive Vice President and Chief Scientific Officer will leave the company to pursue other interests.

**David H. Solomon, President and CEO of Zealand, commented:**

*“On behalf also of our Board of Directors, I wish to thank Christian for his valuable contributions to Zealand. During his tenure with the company, Christian has been instrumental in the advancement of our innovative peptide discovery projects and he has played an important role in establishing new preclinical drug candidates to support our pipeline. We wish him the best of luck with his future endeavors.”*

A search for a successor to Christian Grøndahl in the position as Chief Scientific Officer is underway.

###

**For further information, please contact:**

**Zealand Pharma A/S**

David Solomon, President and Chief Scientific Officer  
Tel: +45 22 20 63 00

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication  
Tel: +45 5060 3689, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)

**About Zealand**

Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2013).

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. For further information: [www.zealandpharma.com](http://www.zealandpharma.com)